Butantan Institute, a biomedical research centre in Brazil, has developed a potential COVID-19 vaccine and will seek regulatory approval to begin human trials, according to two sources familiar with the matter, Reuters news agency reported on Friday,
The sources said that Butantan plans to test the vaccine, named Butanvac, on 1,800 volunteers over two phases.
This vaccine has been 100% developed in Brazil by an international consortium that also includes Vietnam and Thailand.
Production on a large scale is anticipated to start in May 2021.
OncoHost receives BIG Innovation Award in Health category
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025